Truist Financial Corp purchased a new position in Abcam plc (NASDAQ:ABCM – Get Rating) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,158 shares of the company’s stock, valued at approximately $332,000.
A number of other hedge funds have also made changes to their positions in the stock. National Bank of Canada FI acquired a new position in Abcam in the 4th quarter valued at approximately $26,000. HM Payson & Co. purchased a new position in shares of Abcam during the 4th quarter valued at $29,000. Advisor Group Holdings Inc. increased its stake in shares of Abcam by 20.5% in the fourth quarter. Advisor Group Holdings Inc. now owns 5,876 shares of the company’s stock worth $138,000 after acquiring an additional 999 shares during the last quarter. ARK Investment Management LLC raised its holdings in shares of Abcam by 19.0% during the first quarter. ARK Investment Management LLC now owns 9,873 shares of the company’s stock worth $181,000 after acquiring an additional 1,575 shares in the last quarter. Finally, Diversified Trust Co boosted its position in Abcam by 14.6% during the first quarter. Diversified Trust Co now owns 11,200 shares of the company’s stock valued at $205,000 after purchasing an additional 1,425 shares during the last quarter. 16.80% of the stock is owned by hedge funds and other institutional investors.
Abcam Stock Performance
Abcam stock opened at $15.03 on Friday. Abcam plc has a 1-year low of $12.54 and a 1-year high of $24.00. The firm’s fifty day simple moving average is $14.52 and its 200-day simple moving average is $16.09.
Wall Street Analyst Weigh In
Separately, Royal Bank of Canada cut their price target on Abcam from GBX 1,950 ($23.49) to GBX 1,700 ($20.48) in a research note on Tuesday, May 10th.
Abcam Profile
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Featured Stories
Want to see what other hedge funds are holding ABCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abcam plc (NASDAQ:ABCM – Get Rating).
Receive News & Ratings for Abcam Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abcam and related companies with MarketBeat.com’s FREE daily email newsletter.
Read More: Truist Financial Corp Buys Shares of 18,158 Abcam plc (NASDAQ:ABCM)